Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katarina LeBlanc

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Stem Cell Research & Therapy|June 18, 2020
Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells-first phase I/II human clinical study: commentary to responseStellan Hertegård, Katarina LeBlanc
Annals of Internal Medicine|June 18, 2003
SimvastatinKatarina LeBlanc, Mary T Brophy
Nature Medicine|July 10, 2013
MSCs: science and trialsWillem E Fibbe, Francesco Dazzi, Katarina LeBlanc
Stem Cell Research & Therapy|March 22, 2020
Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells-first phase I/II human clinical studyStellan Hertegård, Srinivasa Rau Nagubothu, Emma Malmström, et al.
Pediatric Transplantation|November 16, 2011
Donor cell-derived acute myeloid leukemia after second allogenic cord blood transplantation in a patient with Fanconi anemiaBritt Gustafsson, Jacob Moell, Katarina Leblanc, et al.
Stem Cells and Development|December 14, 2020
The Coronavirus Pandemic: A Pitfall or a Fast Track for Validating Cell Therapy Products?Maroun Khoury, Laertis Ikonomou, Massimo Dominici, et al.
European Journal of Haematology|July 7, 2012
Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantationUlrica Forslöw, Ola Blennow, Katarina LeBlanc, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 3, 2004
Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemiaAnna Nordlander, Jonas Mattsson, Olle Ringdén, et al.
British Journal of Haematology|September 16, 2006
Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimensMats Merup, Vladimir Lazarevic, Hareth Nahi, et al.
Cytotherapy|March 14, 2021
Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predispositionJacques Galipeau, Mauro Krampera, Katarina Leblanc, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Stem Cell Research & Therapy|June 18, 2020
Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells-first phase I/II human clinical study: commentary to responseStellan Hertegård, Katarina LeBlanc
Annals of Internal Medicine|June 18, 2003
SimvastatinKatarina LeBlanc, Mary T Brophy
Nature Medicine|July 10, 2013
MSCs: science and trialsWillem E Fibbe, Francesco Dazzi, Katarina LeBlanc
Stem Cell Research & Therapy|March 22, 2020
Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells-first phase I/II human clinical studyStellan Hertegård, Srinivasa Rau Nagubothu, Emma Malmström, et al.
Pediatric Transplantation|November 16, 2011
Donor cell-derived acute myeloid leukemia after second allogenic cord blood transplantation in a patient with Fanconi anemiaBritt Gustafsson, Jacob Moell, Katarina Leblanc, et al.
Stem Cells and Development|December 14, 2020
The Coronavirus Pandemic: A Pitfall or a Fast Track for Validating Cell Therapy Products?Maroun Khoury, Laertis Ikonomou, Massimo Dominici, et al.
European Journal of Haematology|July 7, 2012
Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantationUlrica Forslöw, Ola Blennow, Katarina LeBlanc, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 3, 2004
Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemiaAnna Nordlander, Jonas Mattsson, Olle Ringdén, et al.
British Journal of Haematology|September 16, 2006
Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimensMats Merup, Vladimir Lazarevic, Hareth Nahi, et al.
Cytotherapy|March 14, 2021
Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predispositionJacques Galipeau, Mauro Krampera, Katarina Leblanc, et al.
Pageof 2